Currently shipping.

Menactra: Currently, sanofi pasteur reports that the supply of MCVH is adequate to resume vaccinating all recommended groups. Those include: 11 - 12 year olds, 15 year old high school freshman and 18 year old college freshman living in dorms.

Note: As of October 4, 2005, the Vaccine Adverse Event Reporting System (VAERS) received five reports of Guillain-Barre syndrome (GBS) in persons after receipt of Menactra (MCV4) vaccination.  All reported GBS cases occurred among person aged 17-18 years who were vaccinated during June 10-July 25, 2005 and had symptom onset 14-31 days after MCV4 vaccination.  The rate of GBS based on the number of cases reported within 6 weeks of administration of MCV4 is similar to what might have been expected to occur by chance alone.  However, the timing of the onset of neurologic symptoms (i.e., within 2-5 weeks of vaccination) is of concern.  FDA and CDC are requesting that providers or other persons with knowledge of possible cases of GBS (or clinically significant adverse events) occurring after vaccination with MCV4 report them to VAERS.  Reports of GBS should be submitted to VAERS at http://www.vaers.hhs.gov or by telephone at 1-800-822-7967.